P/E ratio for Rigel Pharmaceuticals (RIGL)
P/E ratio as of April 2024 (TTM): -5.00
According to Rigel Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5. At the end of 2022 the company had a P/E ratio of -4.41.
P/E ratio history for Rigel Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -4.41 | -83.35% |
| 2021 | -26.5 | 21.14% |
| 2020 | -21.9 | 308.88% |
| 2019 | -5.35 | 4.67% |
| 2018 | -5.11 | -19.64% |
| 2017 | -6.36 | 97.77% |
| 2016 | -3.22 | -37.37% |
| 2015 | -5.14 | 133.02% |
| 2014 | -2.20 | -21.9% |
| 2013 | -2.82 | -42.26% |
| 2012 | -4.89 | -13.9% |
| 2011 | -5.68 | -155.03% |
| 2010 | 10.3 | -397.2% |
| 2009 | -3.47 | 58.79% |
| 2008 | -2.19 | -77.79% |
| 2007 | -9.84 | 25.19% |
| 2006 | -7.86 | 95.58% |
| 2005 | -4.02 | -48.65% |
| 2004 | -7.83 | 104.24% |
| 2003 | -3.83 | 184.51% |
| 2002 | -1.35 | -35.11% |
| 2001 | -2.08 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 19.1 | -481.60% | 🇺🇸 USA |
 AstraZeneca AZN | 37.9 | -857.38% | 🇬🇧 UK |
 Sangamo Therapeutics
SGMO | -0.3615 | -92.77% | 🇺🇸 USA |
 ChemoCentryx CCXI | -27.5 | 450.16% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.